Immune infiltration patterns and identification of new diagnostic biomarkers GDF10, NCKAP5, and RTKN2 in non-small cell lung cancer DOI Creative Commons
Kaiqin Chen, Chun Ye, Zihan Gao

et al.

Translational Oncology, Journal Year: 2023, Volume and Issue: 29, P. 101618 - 101618

Published: Jan. 9, 2023

This study aimed to identify potential biomarkers for non-small cell lung cancer (NSCLC) and analyze the role of immune infiltration in NSCLC. R software was used screen differentially expressed genes (DEGs) from NSCLC datasets obtained Gene Expression Omnibus (GEO) database, functional correlation analysis performed. The machine learning algorithms were diagnostic values assessed through receiver operating characteristic (ROC) curves. protein mRNA expression levels verified based on Human Protein Atlas (HPA) database qRT-PCR. CIBERSORT evaluate cells tissues, between infiltrated analyzed. Finally, specific siRNAs utilized reduce GDF10, NCKAP5, RTKN2 A549 H1975 cells. proliferation ability detected by MTT assay. A total 848 upregulated DEGs 1308 downregulated identified. ontology (GO) Kyoto Encyclopedia Genes Genomes (KEGG) enrichment analyses showed that mainly related division. Disease (DO) diseases with these diseases, including In addition,three identified: RTKN2. Immune resting NK cells, activated dendritic Tregs may be involved pathogenesis Meanwhile, negatively correlated naïve B but positively Immunohistochemical staining tissue patients lower than normal tissue. qRT-PCR also confirmed three lines significantly those human epithelial BEAS-2B. An assay knockdown promoted vitro experiments played inhibitory effects proliferation. Hence, can as

Language: Английский

Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives DOI
Evgeny N. Imyanitov, Aglaya G. Iyevleva, E. Levchenko

et al.

Critical Reviews in Oncology/Hematology, Journal Year: 2020, Volume and Issue: 157, P. 103194 - 103194

Published: Dec. 11, 2020

Language: Английский

Citations

382
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study DOI
Alessandro Rizzo, Veronica Mollica, Valentina Tateo

et al.

Cancer Immunology Immunotherapy, Journal Year: 2023, Volume and Issue: 72(6), P. 1381 - 1394

Published: Jan. 25, 2023

Language: Английский

Citations

112
FOXM1: A small fox that makes more tracks for cancer progression and metastasis DOI Creative Commons
Md Arafat Khan, Parvez Κhan,

Aatiya Ahmad

et al.

Seminars in Cancer Biology, Journal Year: 2023, Volume and Issue: 92, P. 1 - 15

Published: March 22, 2023

Language: Английский

Citations

60
o8G-modified circPLCE1 inhibits lung cancer progression via chaperone-mediated autophagy DOI Creative Commons

Qingyun Zhao,

Dunyu Cai,

Haotian Xu

et al.

Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)

Published: March 17, 2025

Lung cancer poses a serious threat to human health, but its molecular mechanisms remain unclear. Circular RNAs (circRNAs) are closely associated with tumour progression, and the important role of 8-oxoguanine (o8G) modification in regulating fate RNA has been gradually revealed. However, o8G circRNAs not reported. We identified circPLCE1, which is significantly downregulated lung cancer, further investigated circPLCE1 related mechanism progression. differentially expressed by high-throughput sequencing then conducted methylated immunoprecipitation (MeRIP), immunofluorescence (IF) analysis, crosslinking (CLIP) actinomycin D (ActD) assays explore modification. The biological functions vivo vitro were clarified via establishing silencing/overexpression system. Tagged affinity purification (TRAP), Immunoprecipitation (RIP) coimmunoprecipitation (Co-IP) assays, pSIN-PAmCherry-KFERQ-NE reporter gene used elucidate inhibits This study revealed that reactive oxygen species (ROS) can induce AUF1 mediate decrease stability. found inhibited progression expression was stage prognosis. elucidated: targets HSC70 protein, increases ubiquitination level, regulates ATG5-dependent macroautophagy chaperone-mediated autophagy (CMA) pathway, ultimately o8G-modified through CMA inhibit alter cell fate. provides only new theoretical basis for elucidating also potential treatment. ROS modification, specifically recognizes thereby decreases activity, promotes altering cells inhibiting

Language: Английский

Citations

2
NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesis DOI
Deepanwita Sengupta,

Liyong Zeng,

Yumei Li

et al.

Molecular Cell, Journal Year: 2021, Volume and Issue: 81(21), P. 4481 - 4492.e9

Published: Nov. 1, 2021

Language: Английский

Citations

74
Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research DOI Creative Commons
Liusheng Wu,

Yanfeng Zhong,

Xiaoya Yu

et al.

Anti-Cancer Drugs, Journal Year: 2022, Volume and Issue: unknown

Published: Aug. 9, 2022

The aim of this study was to find the application value selective polyadenylation in immune cell infiltration, biological transcription function and risk assessment survival prognosis lung adenocarcinoma (LUAD). processed original mRNA expression data LUAD were downloaded, profiles 594 patient samples collected. (APA) events TCGA-NA-SEQ evaluated by site use Index (PDUI) values, invasion stromal cells tumor purity calculated group select differential genes. Lasso regression stratified analysis used examine role scores predicting outcomes. also GDSC database predict chemotherapeutic sensitivity each sample a method obtain an IC50 estimate for specific drug treatment. Then CIBERSORT algorithm conduct Spearman correlation analysis, regulatory factor TIDE system gene level content. Finally, Kaplan–Meier curve analyze between score LUAD. In study, APA’s prognostic model constructed. KM showed that affected patients ( P = 0.027) but matrix not statistically significant 0.1). We extracted 108 genes with APA from 827 different based on PUDI clustering heat map, rate four groups significantly 0.05). Multiple omics studies positively correlated Macrophages M0, T Follicular helper, B naive NK resting. It is negatively dendritic resting, mast monocyte, CD4 memory resting memory. further explored relationship immunosuppressor found ADORA2A, BTLA, CD160, CD244, CD274, CD96, CSF1R CTLA4 highly score. Selective poly adenylation plays important development progression LUAD, invasion, metastasis transcription, affects patients.

Language: Английский

Citations

65
Pathogenesis and therapeutic strategy in platinum resistance lung cancer DOI
Panpan Lv,

Shuli Man,

Lu Xie

et al.

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2021, Volume and Issue: 1876(1), P. 188577 - 188577

Published: June 4, 2021

Language: Английский

Citations

57
[18F]FDG-PET/CT Radiomics and Artificial Intelligence in Lung Cancer: Technical Aspects and Potential Clinical Applications DOI Creative Commons
Reyhaneh Manafi‐Farid, Emran Askari, Isaac Shiri

et al.

Seminars in Nuclear Medicine, Journal Year: 2022, Volume and Issue: 52(6), P. 759 - 780

Published: June 15, 2022

Lung cancer is the second most common and leading cause of cancer-related death worldwide. Molecular imaging using [18F]fluorodeoxyglucose Positron Emission Tomography and/or Computed ([18F]FDG-PET/CT) plays an essential role in diagnosis, evaluation response to treatment, prediction outcomes. The images are evaluated qualitative conventional quantitative indices. However, there far more information embedded images, which can be extracted by sophisticated algorithms. Recently, concept uncovering analyzing invisible data from medical called radiomics, gaining attention. Currently, [18F]FDG-PET/CT radiomics growingly lung discover if it enhances diagnostic performance or implication management cancer. In this review, we provide a short overview technical aspects, as they discussed different articles special issue. We mainly focus on [18F]FDG-PET/CT‐based artificial intelligence non-small cell cancer, impacting early detection, staging, tumor subtypes, biomarkers, patient's

Language: Английский

Citations

56
State-of-the-Art and Upcoming Innovations in Pancreatic Cancer Care: A Step Forward to Precision Medicine DOI Open Access
Tommaso Schepis, Sara Sofia De Lucia, Antonio Pellegrino

et al.

Cancers, Journal Year: 2023, Volume and Issue: 15(13), P. 3423 - 3423

Published: June 30, 2023

Pancreatic cancer remains a social and medical burden despite the tremendous advances that medicine has made in last two decades. The incidence of pancreatic is increasing, it continues to be associated with high mortality morbidity rates. difficulty early diagnosis (the lack specific symptoms biomarkers at stages), aggressiveness disease, its resistance systemic therapies are main factors for poor prognosis cancer. only curative treatment surgery, but vast majority patients have advanced disease time diagnosis. surgery among most challenging surgical procedures, recent improvements techniques, careful patient selection, availability minimally invasive techniques (e.g., robotic surgery) dramatically reduced surgery. Patients who not candidates may benefit from locoregional therapy. In some cases whom marginal resection feasible), therapy considered bridge allow downstaging cancer; other metastatic disease), standard approach goal prolonging survival. complexity requires personalized multidisciplinary choose best each clinical situation. aim this article provide literature review available treatments different stages

Language: Английский

Citations

36
Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments—a systematic review DOI Open Access
Alejandro Olivares-Hernández, Elisabet González-Del Portillo, Álvaro Tamayo-Velasco

et al.

Annals of Translational Medicine, Journal Year: 2023, Volume and Issue: 11(10), P. 354 - 354

Published: Aug. 1, 2023

Background: The introduction of immunotherapy in the treatment non-small cell lung cancer (NSCLC) has resulted a radical change patients’ responses and survival rates. increased percentage long survivors, improved toxicity profiles compared to chemotherapy, possible applications for different NSCLC scenarios, have led immune checkpoint inhibitors (ICIs) becoming cornerstone treatment. Therefore, objective this review is describe current future perspectives Methods: A systematic according PRISMA criteria been performed based on clinical trials with from start these treatments until June 2022. Results: use ICIs widespread across both first- second-line anti-PD-1, anti-PD-L1, anti-CTLA-4 drugs. New indications focused adjuvant (atezolizumab) neoadjuvant (nivolumab), now present all stages Given promising results seen trials, new [anti- lymphocyte activation gene-3 (LAG-3) or IDO1] currently under development, will soon be used as standard NSCLC. Conclusions: Immunotherapy mainstay stages, including adjuvant, advanced tumors. development molecules revolutionize coming years.

Language: Английский

Citations

25